Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:131

Article

Patel, Deepen¹  Couroux, Peter¹  Hickey, Pascal²  Salapatek, Anne Marie¹  Laidler, Paul³  Larche, Mark^4,5,6  Hafner, Roderick P.³ 

[1] Cetero Res, Mississauga, ON, Canada

[2] Adiga Life Sci, Hamilton, ON, Canada

[3] Circassia Ltd, Magdalen Ctr, Oxford OX4 4GA, England

[4] McMaster Univ, Dept Med, Clin Immunol & Allergy Div, Hamilton, ON, Canada

[5] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada

[6] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON, Canada

关键词: Allergic rhinitis;    allergic rhinoconjunctivitis;    cat allergy;    environmental exposure chamber;    Fel d 1 peptide immunotherapy;    T-cell epitope;    immune tolerance;    persistence;   

DOI  :  10.1016/j.jaci.2012.07.028

来源: Elsevier

【 摘 要 】

Background: Allergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma. Objectives: We sought to probe the persistence of the treatment effect of a novel Fel d 1-derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy-induced rhinoconjunctivitis after standardized allergen challenge. Methods: In a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment. Results: Treatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = 5.0342) and placebo (P = 5.0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year. Conclusions: A short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment. (J Allergy Clin Immunol 2013;131:103-9.)

【 授权许可】

Free